Definition and pathophysiology

  • Ehlers-Danlos syndrome (EDS) is a heterogeneous group of inherited connective tissue disorders characterized by hyperelastic skin, hypermobile joints, and vascular and other tissue fragility
  • defects in connective tissue cause the signs and symptoms, which range from mild joint hypermobility to life-threatening complications
  • classification from 2017 describes 13 subtypes (Malfait, 2017)
    • inheritance pattern varies by EDS type
    • mutations in at least 20 genes have been identified (e.g.,  COL5A1 or COL5A2 mutations cause the classical type)
    • stroke is most commonly associated with type 4 (vascular EDS) with AD inheritance and abnormal type I and III procollagen production (COL3A1gene)
    • some genes associated with recently described types of Ehlers-Danlos syndrome have functions that appear to be unrelated to collagen
  • prevalence of all EDS types is approx. 1 in 5000 individuals worldwide
    • hypermobile and classic forms are the most common (types 1 and 5)
    • most types are rare, often with only a few cases or families described in the literature
  • incidence of vascular pathologies increases with age   [Pepin, 2000]
  • most deaths result from arterial rupture

Clinical presentation

Dissection, aneurysm formation

  • increased risk of cerebrovascular events is associated particularly with the vascular subtype (vEDS)
  • the carotid arteries and ascending aorta are most commonly affected by dissection
    • dissection may lead to ischemic stroke or SAH (intracranial dissection)
  • aneurysms may be multiple; rupture may lead to CCF formation, SAH, or ICH
Dissecting aneurysm of the left ICA and aneurysm of the left vertebral artery in a 48-year-old patient with Ehlers-Danlos syndrome

Carotid-cavernous fistula

  • carotid-cavernous fistula (CCF) usually occurs spontaneously or following head trauma  (Jindal, 2005)
  • most CCFs are direct (due to rupture of the ICA into the cavernous sinus)
    • the bilateral lesion is not uncommon
  • CCF can be visualized by noninvasive vascular imaging, such as magnetic resonance angiography (MRA) and computed tomography angiography (CTA)
  • therapy:  embolization, balloon occlusion

Diagnostic evaluation

  • typical clinical presentation
  • positive family history
  • genetic testing
    • the panel should include at least the COL5A1, COL5A2, COL1A1, and COL1A2 genes
  • if genetic testing is unavailable, electron microscopy (EM) findings can support the clinical diagnosis
    • abnormalities in collagen fibril architecture – irregular fibril diameter, disorganized arrangement, or abnormal interfibrillar spacing
  • vascular imaging – preferably CTA, MRA
clinical subtype abbreviation IP protein
1 Classical EDS cEDS AD type I and V collagen
2 Classical-like EDS clEDS AR tenascin XB
3 Cardiac-valvular cvEDS AR type I collagen
4 Vascular EDS vEDS AD  (COL3A1) type I and III collagen
5 Hypermobile EDS hEDS AD unknown
6 Arthrochalasia EDS aEDS AD type I collagen
7 Dermatosparaxis EDS dEDS AR ADAMTS-2
8 Kyphoscoliotic EDS kEDS AR FKBP22 and LH1
9 Brittle Cornea syndrome BCS AR ZNF469
10 Spondylodysplastic EDS spEDS AR β4GalT7
β3GalT6
ZIP13
11 Musculocontractural EDS (myopatic)
mcEDS AR D4ST1
DSE
12 Myopathic EDS mEDS AD or AR type XII collagen
13 Periodontal EDS pEDS AD C1r or C1s
  • major criteria
    • generalized joint hypermobility (GJH)
    • skin hyperextensibility and atrophic scarring
  • minor criteria
    • easy bruising
    • soft, doughy skin
    • skin fragility (or traumatic splitting)
    • molluscoid pseudotumors
    • subcutaneous spheroids
    • hernia (or history thereof)
    • epicanthal folds
    • complications of joint hypermobility (e.g., sprains, luxation/subluxation, pain, flexible flatfoot)
    • family history of a first-degree relative meeting clinical criteria

Minimal criteria suggestive of cEDS:

skin hyperextensibility and atrophic scarring

+

generalized joint hypermobility (GJH)  and/or  at least 3 minor criteria

Management

  • acute stroke therapy
    • standard stroke protocols and IVT contraindications apply; extra caution is required due to increased risk of bleeding
    • experience with mechanical thrombectomy is limited; increased risk of periprocedural arterial injury can be expected
  • stroke prevention
    • blood pressure control to reduce arterial wall stress
    • antiplatelet agents (secondary prevention)
    • serial imaging studies for detection/follow-up of aneurysms or dissections
  • symptomatic therapy
    • pain anagement (analgesics, neuropathic agents like gabapentin)
    • physical therapy – focused on joint stabilization and muscle strengthening
    • orthotic support
    • cardiovascular monitoring
  • genetic counseling
  • surgical interventions –  generally reserved for life-threatening situations or severe mechanical dysfunction

FAQs

What is Ehlers-Danlos Syndrome (EDS)?
  • EDS is a heterogeneous group of inherited connective tissue disorders characterized by hyperelastic skin, hypermobile joints, and vascular and tissue fragility

What causes EDS?
  • EDS is caused by mutations in genes responsible for collagen production, a crucial protein for connective tissue strength and integrity
  • mutations in at least 20 genes have been identified (e.g.,  COL5A1 or COL5A2 mutations cause the classical type)
  • stroke is most commonly associated with type 4 (vascular EDS) with AD inheritance and abnormal type I and III procollagen production (COL3A1gene)

Is EDS hereditary?
  • yes, EDS is often inherited in an autosomal dominant or recessive manner
What are common complications of EDS?
  • complications include joint dislocations, scoliosis, chronic pain, and, in severe cases, life-threatening cardiovascular conditions (arterial dissection, aneurysm rupture, stroke)

Can individuals with EDS lead a normal life?
  • with proper management, many individuals with EDS can lead active and fulfilling lives, though some may face challenges due to chronic pain or mobility issues

Is there a cure for EDS?
  • currently, there’s no cure, but treatment can manage symptoms and prevent complications

What is Ehlers-Danlos syndrome life expectancy?
  • the overall life expectancy of patients with vascular EDS is shortened, largely as a result of vascular rupture, with a median life span of 48 years (range, 6–73 years)

You cannot copy content of this page

Send this to a friend
Hi,
you may find this topic useful:

Ehlers-Danlos syndrome
link: https://www.stroke-manual.com/ehlers-danlos-syndrome/